Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter's HomeChoice

This article was originally published in The Gray Sheet

Executive Summary

Firm begins full-scale launch of its automated peritoneal dialysis system in the U.S., Europe, and Japan. The product uses pneumatic pressure to create a gravity emulation system that eliminates the need for elevated bags in the measurement and movement of PD solution. HomeChoice has been available on a limited basis since receiving FDA 510(k) clearance in March ('The Gray Sheet" May 23, p. 8). Baxter anticipates being able to fully meet demand for the VCR-sized unit by mid-fall. The company says that HomeChoice will cost about the same as PacXtra, the company's current APD system. Approximately 450 patients have used the product during the limited release, including about 250 in the U.S

You may also be interested in...



Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

MT002724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel